By Maxx Chatsko The women’s health drug specialist rebuffed an offer from its majority shareholder. A roller coaster ride could be ahead. Biotech investors have been faced with a historic correction for the sector, a historic pace of interest rate increases, a historic ruling on regulating drug prices, and generally sour sentiment. Shareholders of Myovant Sciences (MYOV) – Get Myovant Sciences Ltd. Report can now add a family feud to the list. The drug developer, which focuses on women’s and men’s health, turned down a $2.5 billion acquisition offer from Sumitovant Biopharma. According to SEC …